Mitoketoscins : novel mitochondrial inhibitors for targeting ketone metabolism in cancer stem cells (CSCs). by Ozsvari, B et al.
Mitoketoscins : novel mitochondrial 
inhibitors for targeting ketone metabolism 
in cancer stem cells (CSCs).
Ozsvari, B, Sotgia, F, Simmons, K, Trowbridge, R, Foster, R and Lisanti, MP
10.18632/oncotarget.21259
Title Mitoketoscins : novel mitochondrial inhibitors for targeting ketone 
metabolism in cancer stem cells (CSCs).
Authors Ozsvari, B, Sotgia, F, Simmons, K, Trowbridge, R, Foster, R and Lisanti, 
MP
Type Article
URL This version is available at: http://usir.salford.ac.uk/44377/
Published Date 2017
USIR is a digital collection of the research output of the University of Salford. Where copyright 
permits, full text material held in the repository is made freely available online and can be read, 
downloaded and copied for non­commercial private study or research purposes. Please check the 
manuscript for any further copyright restrictions.
For more information, including our policy and submission procedure, please
contact the Repository Team at: usir@salford.ac.uk.
Oncotarget78340www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 45), pp: 78340-78350
Mitoketoscins: Novel mitochondrial inhibitors for targeting 
ketone metabolism in cancer stem cells (CSCs)
Bela Ozsvari1,2, Federica Sotgia1,2, Katie Simmons3, Rachel Trowbridge3, Richard 
Foster3,4 and Michael P. Lisanti1,2
1 Translational Medicine, School of Environment & Life Sciences, University of Salford, Greater Manchester, UK
2 The Paterson Institute, University of Manchester, Withington, UK
3 School of Molecular & Cellular Biology & Astbury Centre for Structural Molecular Biology, Faculty of Biological Sciences, 
University of Leeds, West Yorkshire, UK
4 School of Chemistry, Faculty of Mathematics and Physical Sciences, University of Leeds, West Yorkshire, UK
Correspondence to: Michael P. Lisanti, email: michaelp.lisanti@gmail.com
Correspondence to: Richard Foster, email: r.foster@leeds.ac.uk
Keywords: ketone bodies, drug design, mitochondria, tumor-initiating cells, cancer stem-like cells
Abbreviations: OXCT1, 3-Oxoacid CoA-Transferase 1 (mitochondrial); ACAT1, Acetyl-CoA Acetyltransferase 1 (mitochondrial); 
vHTS, Virtual High-Throughput Screening
Received: July 11, 2017 Accepted: July 31, 2017 Published: September 24, 2017
Copyright: Ozsvari et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Previous studies have now well-established that epithelial cancer cells can 
utilize ketone bodies (3-hydroxybutyrate and aceto-acetate) as mitochondrial fuels, 
to actively promote tumor growth and metastatic dissemination. The two critical 
metabolic enzymes implicated in this process are OXCT1 and ACAT1, which are 
both mitochondrial proteins. Importantly, over-expression of OXCT1 or ACAT1 in 
human breast cancer cells is sufficient to genetically drive tumorigenesis and/or lung 
metastasis, validating that they indeed behave as metabolic “tumor promoters”. Here, 
we decided to target these two enzymes, which give cancer cells the ability to recycle 
ketone bodies into Acetyl-CoA and, therefore, to produce increased ATP. Briefly, we 
used computational chemistry (in silico drug design) to select a sub-set of potentially 
promising compounds that spatially fit within the active site of these enzymes, 
based on their known 3D crystal structures. These libraries of compounds were then 
phenotypically screened for their effects on total cellular ATP levels. Positive hits 
were further validated by metabolic flux analysis. Our results indicated that four of 
these compounds effectively inhibited mitochondrial oxygen consumption. Two of 
these compounds also induced a reactive glycolytic phenotype in cancer cells. Most 
importantly, using the mammosphere assay, we showed that these compounds can be 
used to functionally inhibit cancer stem cell (CSC) activity and propagation. Finally, our 
molecular modeling studies directly show how these novel compounds are predicted 
to bind to the active catalytic sites of OXCT1 and ACAT1, within their Coenzyme A 
binding site. As such, we speculate that these mitochondrial inhibitors are partially 
mimicking the structure of Coenzyme A. Thus, we conclude that OXCT1 and ACAT1 are 
important new therapeutic targets for further drug development and optimization. 
We propose that this new class of drugs should be termed “mitoketoscins”, to reflect 
that they were designed to target ketone re-utilization and mitochondrial function.
                                                               Research Paper
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INTRODUCTION
Ketones (3-hydroxybutyrate, acetoacetate and 
acetone) are high-energy mitochondrial fuels; they are 
naturally generated by hepatocytes, during periods of 
caloric restriction, fasting and/or starvation [1-3]. During 
nutrient deprivation, ketone bodies secreted into the blood 
are then directed towards the brain, where neurons convert 
them back into Acetyl-CoA, so they can be effectively re-
utilized as an energy source [1-3]. The two most critical 
neuronal enzymes for this ketone re-utilization process are 
OXCT1 and ACAT1 [2, 3], as they are directly involved 
in the conversion of ketone bodies into Acetyl-CoA, 
so that they can re-enter the TCA cycle and generate 
mitochondrially-derived ATP. 
Recently, we showed that a similar “ketone-shuttle” 
also exists in human tumors, whereby ketogenic cancer-
associated fibroblasts (CAFs) locally produce ketone 
bodies, for their re-utilization by mitochondria in adjacent 
human breast cancer cells [2-8]. In further support of 
this “metabolic-coupling” hypothesis, recombinant over-
expression of ACAT1 or OXCT1 in MDA-MB-231 breast 
cancer cells was indeed sufficient to promote tumor 
growth and lung metastasis [4]. These data provide genetic 
evidence that ketone body re-utilization can help drive 
tumor progression and metastasis [4, 5].
Using a metabolo-genomics approach, we also 
tested the effects of ketone bodies on the transcriptional 
profile of MCF7 breast cancer cells [8]. Interestingly, 
we observed that these ketone-induced mRNA profiles 
were most tightly associated with (1) stemness (neural, 
embryonic and hematopoietic), (2) a reduction in DNA 
damage and (3) breast cancer (ER-negative vs. ER-
positive) [8]. Most importantly, the ketone-induced “gene 
signature” was able to predict poor clinical outcome 
(including recurrence and metastasis), in ER(+) human 
breast cancer patients. In accordance with these findings, 
treatment of embryonic stem (ES) cells with ketone bodies 
was sufficient to enhance their “stemness phenotype”. For 
example, ES cell colony size (diameter) was increased up 
to 25%, while colony number was increased by ~2-3-fold 
[8].
Based on these and other ketone-related studies, it 
appears that the enzymes driving ketone re-utilization, 
namely ACAT1 and OXCT1, would be excellent 
therapeutic targets for drug development, especially for 
the eradication of cancer stem cells (CSCs). Here, we 
tested this hypothesis directly, by identifying new small 
molecules to exploit ketone metabolism. Importantly, our 
results directly show that these new chemical entities, 
targeting ACAT1 and OXCT1, are indeed sufficient to 
block CSC propagation and to effectively inhibit oxidative 
mitochondrial metabolism. 
RESULTS
Overall strategy for the discovery of new 
inhibitors of ketone re-utilization and 
mitochondrial metabolism
In order to identify novel metabolic inhibitors to 
target the re-utilization of ketone bodies as mitochondrial 
fuels, we took advantage of the known 3D crystal 
structures of the enzymes responsible for this process, 
namely ACAT1 and OXCT1. Both of these enzymes are 
mitochondrial proteins, which are involved in the chemical 
conversion of ketone bodies into Acetyl-CoA, which 
can then enter the TCA cycle. So, effective ACAT1 and 
OXCT1 inhibitors would be expected to phenotypically 
drive ATP depletion in cancer cells. 
Our overall screening strategy is briefly illustrated 
schematically in Figure 1. First, we used the 3D structure 
of porcine OXCT1 and human ACAT1 proteins to 
virtually screen an in-house library of ~30,000 compounds 
and identified a subset of ~1,000 compounds each that 
are predicted to bind to these proteins in silico. Further 
analysis of predicted binding affinity and visual inspection 
was performed. Compounds performing well in all 
analysis steps (an overall library of 227 compounds) were 
then selected for assay. 
Second, the resulting compound libraries were then 
subjected to phenotypic drug screening at a concentration 
of 20 µM, to identify which compounds functionally 
induce ATP-depletion, before inducing cell death. 
Subsequently, positive hits were re-screened at the same 
and lower concentrations (20 µM and 10 µM), to identify 
the top eight compounds that most potently induced ATP-
depletion. 
Finally, the eight top hits were then further validated 
using 3D mammosphere assays to assess their potential 
anti-cancer stem cell activity. Metabolic flux analysis 
was also performed to determine their specific effects on 
i) mitochondrial oxygen consumption and ii) glycolytic 
activity. 
Thus, the overall hit rate was 8 out of 30,000 
(1/3,750 = 0.03%), if we include both vHTS and 
phenotypic screening. After further validation studies 
focused on anti-CSC activity, only 5 final compounds 
remained (with IC-50’s between 10 and 70 μM), yielding 
an overall hit rate of 5 out of 30,000 (1/6,000 = 0.017%). 
As such, this screening and validation procedure 
specifically excluded 99.98% of the compounds that we 
assessed.
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Functional and metabolic characterization of the 
positive hit compounds
The structures of the eight positive hit compounds 
are shown in Figure 2. More specifically, compounds 1-4 
are derived from the OXCT1 screen, while compounds 
5-8 are from the ACAT1 screen. Interestingly, note that 
compounds 2 and 8 are very structurally similar, indicating 
that some of these compounds could be possibly used to 
target both OXCT1 and ACAT1, at the same time. 
All eight compounds were next screened to 
functionally assess their ability to inhibit mammosphere 
formation, which directly measures cancer “stem cell 
activity”. This assay measures the ability of CSCs to 
undergo clonal anchorage-independent growth, under 
non-adhesive conditions, which is a characteristic of cells 
associated with metastatic potential. Six of the compounds 
successfully inhibited mammosphere formation, with IC-
50’s between 10 and 170 μM (Figure 3). These results are 
also summarized in Table 1. 
Their rank order potency was as follows: 8 > 2 > 6 
> 3 > 5 > 1 > 4. Thus, we decided to focus our efforts on 
the metabolic characterization of the top four compounds 
(8 > 2 > 6 > 3), with IC-50’s between 10 and 50 μM. In 
this context, it is important to note that compounds 8 and 
2 are nearly structurally identical, and as such functionally 
show extremely similar IC-50’s between 10 -to- 11 μM for 
targeting the propagation of CSCs. 
Figure 1: Schematic diagram illustrating our overall drug discovery strategy, employing both in silico and phenotypic 
drug screening. 1. Virtual high-throughput screening (vHTS) - We used the 3D structure of porcine OXCT1 and human ACAT1 proteins 
to screen a virtual collection of 30,000 compounds and identified a subset of 1,000 compounds each that “bind” in silico. Further analysis 
of predicted binding affinity and visual inspection was performed. Compounds performing well in all analysis steps were then selected for 
assay. 2. Phenotypic drug screening - The resulting compound libraries were then subjected to phenotypic drug screening at a concentration 
of 20 µM, to identify which compounds functionally induce ATP-depletion, before inducing cell death. Subsequently, positive hits were 
re-screened at the same and lower concentrations (20 µM and 10 µM), to identify the top eight compounds that most potently induced 
ATP-depletion. 3. Functional validation - The top hits were then further validated using mammosphere assays (for assessing potential anti-
cancer stem cell activity). Metabolic flux analysis, to determine specific effects on oxygen consumption, to estimate their anti-mitochondrial 
activity, and viability assays were also carried out. 
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Figures 4, 5 and 6 show that compounds 2, 3, 6 
and 8 all successfully targeted mitochondrial oxygen 
consumption (OCR} as predicted, driving ATP depletion, 
as measured by using the Seahorse XF metabolic flux 
analyzer. In addition, compounds 3 and 5 significantly 
stimulated aerobic glycolysis in the cancer cells (ECAR; 
Figure 7). 
Molecular modeling of hit compounds: docking 
within the active catalytic sites of OXCT1 and 
ACAT1
Figure 8 illustrates the predicted binding sites of the 
top four hit compounds and their binding partners. 
More specifically, we show the docking predicted, 
using the vHTS program eHiTS, of compounds 2 and 3 
at the succinyl-CoA binding site within the 3D crystal 
structure of OXCT1. Similarly, we depict the predicted 
docking of compounds 6 and 8, at the CoA binding site of 
3D crystal structure of ACAT1. 
This type of key structural and topological 
Table 1: IC-50 values for the mitoketoscins
IC-50 values of top hit compounds are shown highlighting 
their efficacy in the 3D-spheroid assay for detecting CSC 
activity.
Compounds 1 to 4 are hits from the OXCT1 screen. 
Compounds 5 to 8 are hits from the ACAT1 screen. 
Figure 2: Chemical structures of the top 8 hits. OXCT1 
hits: a) compound 1 (ALB-H01004577); b) compound 2 
(ALB-H09465625); c) compound 3 (ALB-H15358970); d) 
compound 4 (ALB-H15354504); ACAT1 hits: e) compound 
5 (ALB-H04367562); f) compound 6 (LEG19576081); 
g) compound 7 (ALB-H10747299); h) compound 8 
(ALB-H01005022).
Figure 3: Effects of the top 6 hit compounds on 
mammosphere formation. Compound 2 and 8 (Panel A. 
and B.) were the two most potent hits in decreasing the number 
of mammospheres, a measure of cancer stem cell activity, at a 
concentration of 25 µM. Compound 6 and 3 were also effective 
(see panel C. and D.), while compound 5 and 1 (panel E. and F.) 
were less potent inhibitors of mammosphere growth. Compound 
4 had no effect; compound 7 was excluded in this experiment 
due to solubility problems. Bar graphs are shown as the mean 
± SEM; t-test, two-tailed test *p < 0.05, **p < 0.005, ***p < 
0.0001.
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Figure 4: Effects of the top 4 hit compounds on the 
metabolic activity of MCF7 human breast cancer 
cells. Oxygen consumption rate (OCR) was measured using 
the Seahorse XFe96 Metabolic Flux Analyzer. Then data were 
normalized to protein content (SRB assay). Note that compound 
2 or 8 treatments reduced mitochondrial respiration significantly 
even at a dose as low as 5 µM (see panel A. and B.). Compound 
6 and 3 were also potent inhibitors (panel C. and D.). MCF7 
cells were treated with each compound for 72 hours. 
Figure 5: Quantitation of respiration and ATP production 
in MCF7 cells treated with compounds 2 (A) and 8 
(B). Their effects on basal respiration, the proton leak, ATP 
production, maximal respiration and spare respiratory capacity 
are all shown. See Figure 4 for additional details. 
Figure 6: Quantitation of respiration and ATP production 
in MCF7 cells treated with compounds 6 (A) and 3 
(B). Their effects on basal respiration, the proton leak, ATP 
production, maximal respiration and spare respiratory capacity 
are all shown. See Figure 4 for additional details.
Figure 7: Comparative metabolic flux analysis of 
the top 5 hit compounds in MCF7 cells. Extracellular 
acidification rate (ECAR) was measured using the Seahorse 
XFe96 Metabolic Flux Analyzer (A). Then data were normalized 
to protein content (SRB assay) (B). Note that compound 3 
and 5 treatment stimulated glycolysis significantly, at the 
concentrations displayed in the graph. MCF7 cells were treated 
with each compound for 72 hours. 
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information will be important for the further optimization 
of these hit compounds, for the more potent targeting of 
OXCT1 and ACAT1, in future studies. 
DISCUSSION
Discovery of the mitoketoscins: targeting 
mitochondrial OXCT1 and ACAT1
Ketone bodies functionally behave as mitochondrial 
fuels, which can actively drive tumor growth and 
metastasis. In this context, OXCT1 and ACAT1 are 
two mitochondrial proteins that participate in ketone 
re-utilization (summarized in Figure 9). For example, 
recombinant transduction of human breast cancer cells 
(MDA-MB-231) with either OXCT1 or ACAT1 is indeed 
sufficient to metabolically promote tumor growth and 
metastasis, in pre-clinical models. Based on these findings, 
we proposed that they function as “metabolic oncogenes”. 
In this report, we molecularly targeted OXCT1 and 
ACAT1, to prevent cancer cells from recycling ketone 
bodies into Acetyl-CoA, which normally enters the 
TCA cycle, driving mitochondrial ATP production. 
More specifically, we employed an in silico drug design 
approach (computational chemistry) to identify a sub-
set of molecules that chemically fit within the active 
site of OXCT1 or ACAT1, as determined based on their 
published 3D crystal structures. 
These compound libraries were then subjected 
to phenotypic drug screening to identify molecules that 
selectively induce ATP depletion. The resulting positive 
hits were functionally validated further, by using the 
Seahorse XF, to quantitatively measure mitochondrial 
oxygen consumption (OCR) and glycolytic (ECAR) 
rates. Importantly, four of the positive hits inhibited 
mitochondrial oxidative metabolism and two of the 
positive hits also induced a reactive increase in aerobic 
glycolysis. The overall chemical structures of these 
four positive hits are shown in Figure 10. Similarly, 
we used the mammosphere assay to assess cancer stem 
cell activity. Importantly, we showed that these four hit 
compounds significantly inhibit CSC propagation, with 
IC-50’s in the micro-molar range (10 and 170 μM). Our 
molecular modeling studies also reveal how these small 
molecules presumably bind, within the active site of 
OXCT1 and ACAT1. As such, we believe that OXCT1 
and ACAT1 are critical “druggable” targets, for continued 
therapeutic development. Here, we propose the new term 
“mitoketoscins”, to reflect that these small molecules were 
specifically designed to target ketone re-utilization and to 
Figure 8: Docking images of the top 4 hits. Compound 2 docking at the succinyl-CoA binding site of 3-oxoacid CoA-transferase 1 
(OXCT1) (Panel A); compound 8 docking at the CoA binding site of human acetyl-CoA acetyltransferase (ACAT1) (Panel B). Compound 
3 docking at the succinyl-CoA binding site of 3-oxoacid CoA-transferase 1 (OXCT1) (Panel C); compound 6 docking at the CoA binding 
site of human acetyl-CoA acetyltransferase (ACAT1) (Panel D).
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Figure 10: Chemical structures of novel OXCT1 and 
ACAT1 inhibitors. A. The 4 top positive hit compounds 
and their IC-50’s for inhibiting CSC propagation are shown. B. 
The chemical structure of arecoline is shown for comparison. 
Arecoline is a naturally occurring ACAT1 inhibitor. 
Figure 11: Structure activity relationships (SAR) for 
compounds 3 and 4. A. Note that compounds 3 and 4 are 
nearly structurally identical, but compound 3 is approximately 
4 times more potent for targeting CSC propagation. Arrows 
highlight their structural differences. B. The pharmacophore for 
compounds 2 & 8 is shown for comparison. 
Figure 9: Schematic diagram summarizing how 
OXCT1 and ACAT1 are thought to fuel mitochondrial 
metabolism. Note that OXCT1 and ACAT1 functionally 
convert ketone bodies (3-hydroxy-butyrate and aceto-acetate) 
into Acetyl-CoA, which can then enter the mitochondrial TCA 
cycle, driving ATP production. As such, ketone bodies fuel 
tumor growth and metastasis, via mitochondrial metabolism. 
Figure 12: Structure of Coenzyme A (CoA) and 
comparison with hit compounds 2 and 8. A. The structure 
of CoA is shown. Note that it consists of cysteine, pantothenate 
(vitamin B5), adenosine and a series of phosphate groups. A blue 
arrow points at the Acetyl-group of Acetyl-CoA. B. The structure 
of CoA is shown and is compared with top hit compounds 2 
and 8. An area of potentially interesting structural similarity is 
highlighted, using blue ovals. 
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ultimately block mitochondrial metabolism. However, 
we more broadly define “mitoketoscins” as any small 
molecule(s) or peptide(s) that bind to ACAT/OXCT 
gene family members and, as a consequence, inhibit 
mitochondrial function, i.e., ACAT/OXCT inhibitors.
Interestingly, our top hit for the OXCT1 screen 
(compound 2) and our top hit for the ACAT1 screen 
(compound 8) are nearly identical chemically, with 
the exception of minor functional side groups (Figure 
10). So, in essence, the underlying “chemical scaffold” 
or pharmacophore is the same for both of these small 
molecules (Figure 11). This is perhaps not surprising 
since OXCT1 and ACAT1 are two enzymes within the 
same metabolic pathway, and they both handle very 
similar metabolic substrates. However, it is actually 
quite encouraging that using these two independent and 
divergent approaches (OXCT1 versus ACAT1 vHTS) that 
two structurally similar small molecules are functionally 
selected by phenotypic screening from these two different 
starting points. Compound 2 was initially selected for its 
ability to bind “in silico” to the succinyl-CoA binding site 
in OXCT1. Similarly, Compound 8 was originally selected 
for its ability to bind “in silico” to the CoA binding site in 
ACAT1. Therefore, the most likely possibility is that these 
two inhibitors are somehow chemically mimicking the 
structure of Coenzyme A. The structure of compounds 2 
and 8 is also compared to the molecular structure of 
Coenzyme A (CoA; Figure 12), which illustrates some 
recognizable similarities.
In addition, two of the molecules from the OXCT1 
screen (compounds 3 and 4) are chemically similar 
to each other (Figure 11). However, based on their 
observed IC-50 values, compound 3 is nearly 4 times 
more potent than compound 4, in its ability to target 
CSC propagation. The unique chemical groups that 
distinguish these two molecules structurally (highlighted 
by arrows), may therefore be responsible for the observed 
differences in their IC-50’s observed for their inhibition 
of CSC propagation. This structure-activity relationship 
(SAR) will undoubtedly facilitate and allow for further 
optimization of compound 3. 
Arecoline, a natural ACAT1 inhibitor
In a recent report, Fan, Chen and colleagues 
provided additional evidence of a role for ACAT1 as an 
oncogene, using pre-clinical models [9,10]. Moreover, 
they screened a chemical library containing mainly FDA-
approved drugs and identified arecoline, a natural product 
as a potential ACAT1 inhibitor [9,10]. Arecoline is a 
nicotinic acid-based alkaloid found within the areca nut, 
which is the fruit of the areca palm tree (Areca catechu) 
[11]. In certain Asian countries, arecoline is administered 
by chewing the areca nut, together with the betel leaf 
(like chewing tobacco), as it behaves as a natural CNS 
stimulant [11]. Importantly, this natural product, arecoline, 
showed anti-tumor activity, further validating that drugs 
targeting ACAT1 might be valuable as anti-cancer agents 
[9,10]. However, the authors did not assess its capacity to 
target CSCs. As arecoline is very small molecule (shown 
in Figure 10B for comparison), it would need to be 
modified significantly by medicinal chemistry to increase 
its potency. 
Ketone bodies as a mitochondrial fuel source for 
CSCs
Why would CSCs favor the exploitation of ketone 
bodies over other energy-rich metabolic substrates for 
oxidation? The reason may be related to oxidative stress. 
Ketone bodies are metabolized by mitochondria, under 
conditions that dramatically reduce and/or minimize ROS 
production [12-17]. This may be especially beneficial 
to CSCs, as they are already under a significant amount 
of “oncogenic stress”, due to the activation of multiple 
oncogenic driver mutations and the loss of tumor 
suppressor function, resulting in increased oxidative 
stress. Thus, the utilization of ketone bodies may provide 
CSCs with a significant amount of relief/protection 
against ROS production, thereby preventing the onset of 
oncogene-induced senescence. As such, the use of ketone 
Figure 13: Mitoketoscin therapy: Possible follow-
up treatment with mitochondrial substrates. The 
potential side-effects of ketone inhibitors could be significantly 
ameliorated or “controlled” by including a “rescue” step, 
consisting of follow-up treatment with other mitochondrial 
substrates, such as glucose, pyruvate, lactate, fatty acids and/or 
acetyl-carnitine. Importantly, the idea of this follow-up treatment 
is extremely feasible, because sterile D-glucose and L-lactate i.v. 
solutions (D5W, D5NS, Lactated Ringer’s) are currently used 
routinely in hospitals for various clinical indications.
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bodies as a fuel source may help “shield” CSCs against an 
overwhelming amount of mitochondrial-based oxidative 
stress. Thus, removal of this “shield” against endogenous 
ROS, by employing ACAT1 and OXCT1 inhibitors, would 
be expected to contribute significantly to the eradication 
of CSCs. 
It is important to note that while normal ketone 
metabolism occurs strictly under conditions of 
organismal starvation and/or severe nutrient deprivation, 
this regulation is lost in human tumors, and ketone 
metabolism appears to occur constitutively in cancer 
cells. Therefore, the targeting of ketone metabolism in 
human tumors, under normal dietary conditions, would 
be predicted to have minimal metabolic side effects. Also, 
the potential side-effects of ketone inhibitors could be 
significantly ameliorated or “controlled” by including a 
“rescue” step, consisting of a follow-up treatment with 
other mitochondrial substrates, such as glucose, pyruvate, 
lactate, fatty acids and/or acetyl-carnitine (Figure 13). 
Sterile D-glucose and L-lactate i.v. solutions (D5W, D5NS, 
Lactated Ringer’s) are already used routinely in hospitals 
for other clinical and therapeutic indications, making the 
idea of a follow-up treatment extremely feasible. 
CONCLUSIONS
In summary, here we used a computational 
chemistry approach, together with phenotypic drug 
screening and metabolic flux analysis, to develop and 
functionally validate novel small molecule inhibitors 
of OXCT1 and ACAT1. Their ability to functionally 
target CSC propagation was directly validated using the 
mammosphere assay, as a “classic” measure of stem cell 
activity. Molecular modeling revealed how we believe that 
these small molecules fit within the active site of these 
enzymes, which will allow for further modification and 
refinement of their structures by medicinal chemistry 
approaches. 
MATERIALS AND METHODS
Materials
MCF7 cells were purchased from the ATCC 
(American Type Culture Collection). Gibco-brand 
cell culture media (DMEM) was purchased from Life 
Technologies. The top 8 hit compounds were custom-
synthesized and purchased from Avistron Chemistry Inc. 
(United Kingdom). 
Virtual high-throughput screening (vHTS)
Compounds were selected from a screening 
collection of 30,000 compounds. Initial virtual high-
throughput screening (vHTS) used the eHiTS screening 
program [18] to identify the top 1,000 ranked compounds 
both for the OXCT1 and ACAT1 screen based on predicted 
binding affinity to the succinyl-CoA: 3-ketoacid CoA 
transferase from pig heart covalently bound to CoA (PDB 
code 3OXO) or based on predicted binding affinity to the 
CoA binding site of human mitochondrial acetoacetyl-CoA 
thiolase (PDB code 2F2S). Consensus scoring of these top 
1,000 compounds was carried out using AutoDock 4.2 [19] 
followed by further analysis of predicted binding affinity 
and visual inspection using the de novo design program 
SPROUT [20]. Compounds performing well in all analysis 
steps were selected for assay. A total of 227 compounds 
performing well in these analysis steps were then selected 
for phenotypic drug screening. In summary, 84 out of 
30,000 compounds (0.0028 or 0.28%) were selected for 
the OXCT1-based phenotypic screen. Similarly, 143 out 
of 30,000 compounds (0.0048 or 0.48%) were selected for 
the ACAT1-based phenotypic screen. 
Phenotypic drug screening, with a metabolic ATP-
depletion assay
MCF7 cells (6,000 cells/well) were plated into 
black clear-bottom 96-well plates and incubated overnight 
before treatment. The resulting 227 compounds first 
identified by vHTS (84 compounds for the OXCT1 screen 
and 143 compounds for the ACAT1 screen); were then 
subjected to phenotypic drug screening at a concentration 
of 20 μM, to identify which compounds functionally 
induce ATP-depletion, before inducing cell death. 
Subsequently, positive hits were re-screened at lower 
concentrations (10 μM), to identify the top 8 compounds 
that most potently induced ATP-depletion. Compounds 
were tested after 72 hours of incubation and experiments 
were performed in duplicate. After treatment, media was 
aspirated from the wells and plates were washed with 
warm PBS (supplemented w/ Ca2+ and Mg2+). Then, cells 
were incubated with a Hoechst 33342 (Sigma) staining 
solution (10 µg/ml) for 30 min and washed with PBS (to 
estimate cell viability). Fluorescence was read with a plate 
reader using excitation/emission wave-lengths at 355/460-
nm. Then, the CellTiter-Glo luminescent assay (Promega) 
was performed to measure metabolic activity (ATP 
content) in the very same wells that were treated with a 
given compound. Assays were performed according to the 
manufacturer’s protocol. Fluorescence intensity (Hoechst 
staining) and luminescence intensity (ATP content) was 
normalized to vehicle-alone treated controls and were 
displayed as percent control for comparison. 
Cell viability assay
The Sulphorhodamine (SRB) assay is based on the 
measurement of cellular protein content. After treatment 
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for 72h in 96-well plates, cells were fixed with 10% 
trichloroacetic acid (TCA) for 1h in the cold room, and 
were dried overnight at room temperature. Then, cells 
were incubated with SRB for 15 min, washed twice with 
1% acetic acid, and air dried for at least 1h. Finally, the 
protein-bound dye was dissolved in a 10 mM Tris, pH 8.8, 
solution and read using the plate reader at 540-nm.
Mammosphere formation assays
A single cell suspension of MCF7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich) and 
manual disaggregation (25 gauge needle) [21]. Cells were 
then plated at a density of 500 cells/cm2 in mammosphere 
medium (DMEM-F12/ B27 / 20-ng/ml EGF/PenStrep) 
in non-adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma). Cells 
were grown for 5 days and maintained in a humidified 
incubator at 37°C at an atmospheric pressure in 5% (v/v) 
carbon dioxide/air. After 5 days in culture, spheres >50 
μm were counted using an eye-piece graticule, and the 
percentage of cells plated which formed spheres was 
calculated and is referred to as percent mammosphere 
formation, normalized to vehicle-alone treated controls. 
Mammosphere assays were performed in triplicate and 
repeated three times independently.
Seahorse XFe96 metabolic flux analysis
Extracellular acidification rates (ECAR) and real-
time oxygen consumption rates (OCR) for MCF7 cells 
were determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA) [22-
25]. MCF7 cells were maintained in DMEM supplemented 
with 10% FBS (fetal bovine serum), 2 mM GlutaMAX, 
and 1% Pen- Strep. 5,000 cells per well were seeded into 
XF96-well cell culture plates, and incubated overnight at 
37°C in a 5% CO2 humidified atmosphere. After 24h, cells 
were treated with the top four hit compounds at various 
concentrations (or vehicle alone). After 72h of treatment, 
cells were washed in pre-warmed XF assay media (for 
OCR measurement, XF assay media was supplemented 
with 10mM glucose, 1mM Pyruvate, 2mM L-glutamine 
and adjusted at pH 7.4). Cells were then maintained in 
175 μL/well of XF assay media at 37°C, in a non-CO2 
incubator for 1h. During incubation, 25 μL of of 80mM 
glucose, 9μM oligomycin, 1M 2-deoxyglucose (for 
ECAR measurement) and 25 μL of 10μM oligomycin, 
9μM FCCP, 10μM rotenone, 10μM antimycin A (for OCR 
measurement) in XF assay media was loaded into the 
injection ports of the XFe-96 sensor cartridge. During the 
experiment, the instrument injected these inhibitors into 
the wells at a given time point, while ECAR/OCR was 
measured continuously. ECAR and OCR measurements 
were normalized by protein content (Sulphorhodamine 
B assay). Data sets were analyzed by XFe-96 software, 
using one-way ANOVA and Student’s t-test calculations. 
All experiments were performed in triplicate.
Statistical analyses
Statistical significance was determined using the 
Student’s t-test, values of less than 0.05 were considered 
significant. Data are shown as the mean ± SEM, unless 
stated otherwise.
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